A Study of ZN-c3 in Patients With Ovarian Cancer
Trial Status: active
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Inclusion Criteria
- Histologically or cytologically confirmed high-grade serous epithelial ovarian carcinoma, fallopian tube, or peritoneal carcinoma.
- Subjects must have received 1 or 2 prior therapeutic regimens/lines of therapy in the advanced or metastatic setting.
- Measurable disease per RECIST version 1.1.
- Adequate hematologic and organ function as defined by the following criteria:
- ANC ≥ 1.5 × 10^9/L; excluding measurements obtained within 7 days after daily administration of filgrastim/sargramostim or within 3 weeks after administration of pegfilgrastim.
- Platelet count ≥ 100 × 10^9/L; excluding measurements obtained within 3 days after transfusion of platelets or within 3 weeks after administration of platelet growth factors.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upper limit of normal (ULN). If liver function abnormalities are due to underlying liver metastases, AST and ALT ≤ 5 x ULN.
- Total serum bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the case of Gilbert's disease.
- Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min.
Exclusion Criteria
- Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderline ovarian tumor.
- Any of the following treatment interventions within the specified time frame prior to Cycle 1 Day 1:
- Major surgery within 28 days.
- Radiation therapy within 21 days.
- Autologous or allogeneic stem cell transplant within 3 months. A serious illness or medical condition(s) including, but not limited to, the following:
- Brain metastases that require immediate treatment or are clinically or radiographically unstable.
- Myocardial impairment of any cause.
- Significant gastrointestinal abnormalities.
- Active or uncontrolled infection.
- Any evidence of small bowel obstruction as determined by air/fluid levels on computed tomography (CT) scan, recent hospitalization for small bowel obstruction within 3 months prior to Cycle 1 Day 1, or recurrent paracentesis or thoracentesis within 6 weeks prior to Cycle 1 Day 1.
- Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.
Additional locations may be listed on ClinicalTrials.gov for NCT04516447.
Locations matching your search criteria
United States
Colorado
Aurora
UCHealth University of Colorado Hospital
Status: Active
Contact: Lauren Dabdoub
Phone: 303-724-2208
Denver
University of Colorado
Status: Approved
Contact: Tyler Poon
Phone: 720-848-0300
Email: tyler.poon@cuanschutz.edu
Massachusetts
Boston
Dana-Farber Cancer Institute
Status: Temporarily closed to accrual
Name Not AvailableBrigham and Women's Hospital
Status: Temporarily closed to accrual
Name Not AvailableMissouri
Saint Louis
Siteman Cancer Center at Washington University
Status: Active
Name Not AvailableNew York
New York
Mount Sinai Chelsea
Status: Active
Name Not AvailableNorth Carolina
Durham
Duke University Medical Center
Status: Active
Name Not AvailableTexas
Houston
M D Anderson Cancer Center
Status: Active
Name Not AvailableTrial PhasePhase I
Trial Typetreatment
Lead OrganizationK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Primary IDZN-c3-002
- Secondary IDsNCI-2020-07262
- ClinicalTrials.gov IDNCT04516447